ZEGERID

ZEGERID^® (omeprazole/sodium bicarbonate) is an Immediate-Release Oral proton pump inhibitor (PPI) providing continued acid control for patients with gastroesophagael reflux disease (GERD).

ZEGERID is indicated for:

Short-term treatment (4-8 weeks) of active duodenal ulcer
Short-term treatment (4-8 weeks) of active benign gastric ulcer
Heartburn and other symptoms associated with GERD
Short-term treatment (4-8 weeks) of erosive esophagitis which has been diagnosed in endoscopy
Maintenance of healing of erosive esophagitis (controlled studies do not extend beyond 12 months)
Reduction of risk of upper GI bleeding in critically ill patients (powder for oral suspension only)

ZEGERID Powder for Oral Suspension 40 mg/1680 mg is the only FDA approved PPI for reduction of risk of upper GI bleeding in critically ill patients. Use beyond 14 days has not been evaluated.

To learn more about ZEGERID read the full Prescribing Information and Important Safety Information.

Adobe Acrobat Reader is required to view these documents. Download now.

The content of this website is not a substitute for professional medical advice and should not be interpreted as treatment recommendations or relied on for medical diagnosis or treatment. Please see complete Legal Disclaimer.

This site is intended for the exclusive use of residents of the United States of America.